Expressions of forkhead transcription factor O1 and Kruppel like transcription factor 9 in non-small cell lung cancer and their clinical significances
10.3760/cma.j.issn.1006-9801.2019.05.004
- VernacularTitle:叉头框转录因子O1和Kruppel样转录因子9在非小细胞肺癌中的表达及其临床意义
- Author:
Dengrong HAO
1
;
Xiaofeng LI
;
Yancai PENG
Author Information
1. 陕西省榆林市第一医院胸心外科 718000
- Keywords:
Carcinoma;
non-small-cell lung;
Forkhead transcription factors;
Kruppel like transcription factor 9
- From:
Cancer Research and Clinic
2019;31(5):305-309
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expressions of forkhead transcription factor O1 (FOXO1) and Kruppel like transcription factor 9 (KLF9) in non-small cell lung cancer (NSCLC) and their clinical significances. Methods A total of 102 patients with NSCLC who underwent surgical resection in the First Hospital of Yulin from September 2012 to June 2015 were selected as NSCLC group, and the paracancerous tissues more than 5 cm far from the edge of the cancer tissues were selected as the control group. The relative expressions of FOXO1 and KLF9 mRNA in NSCLC tissues and paracancerous tissues were detected by real-time quantitative polymerase chain reaction (qRT-PCR), and the immunohistochemistry was used to detect the expressions of FOXO1 and KLF9 in NSCLC tissues and paracancerous tissues. According to the mean mRNA expression in NSCLC tissues, FOXO1 and KLF9 were divided into high expression group and low expression group, their relationships with clinicopathological parameters were observed. The correlation of FOXO1 and KLF9 expressions was analyzed by Pearson method, and the survival of patients was analyzed by Kaplan-Meier method, logistic regression analysis was performed on the related factors affecting the prognosis of NSCLC. Results Compared with the control group, the expression level of FOXO1 in NSCLC group increased (1.28±0.47 vs. 2.82±0.15, t = 31.525, P < 0.05), while the expression level of KLF9 decreased (1.04±0.11 vs. 0.34± 0.07, t = 54.222, P < 0.05). The expressions of FOXO1 were lower in NSCLC tissues of patients with lymph node metastasis, high differentiation, and TNM stage Ⅲ-Ⅳ than those in NSCLC tissues of patients without lymph node metastasis, middle and low differentiation, and TNM stage Ⅰ-Ⅱ, and the differences were statistically significant (all P < 0.05). The expressions of KLF9 were higher in NSCLC tissues of patients with lymph node metastasis, high differentiation, and TNM stage Ⅲ-Ⅳ than those in NSCLC tissues of patients without lymph node metastasis, middle and low differentiation and TNM stage Ⅰ-Ⅱ, and the differences were statistically significant (all P < 0.05). Pearson correlation analysis showed that there was no significant correlation between FOXO1 and KLF9 expression (r = 0.154, P = 0.156). Kaplan-Meier analysis showed that the 3-year overall survival rate of FOXO1 high expression group was lower than that of FOXO1 low expression group (10.81％ vs. 60.71％, χ 2 = 27.341, P < 0.01). The 3-year overall survival rate of KLF9 low expression group was lower than that of KLF9 high expression group (26.32％ vs. 61.54％, χ 2 = 8.526, P = 0.003). Logistic regression analysis showed that FOXO1 was a risk factor for the prognosis of NSCLC (OR = 2.682, P = 0.003), and KLF9 was a protective factor for the prognosis of NSCLC (OR = 0.446, P = 0.012). Conclusions The high expression of FOXO1 and the low expression of KLF9 in NSCLC tissues can be used as effective indexes to predict the progression of NSCLC. The expressions of FOXO1 and KLF9 are closely related to the poor prognosis of patients.
